Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Ambarella Inc (AMBA), Chuy’s Holdings Inc (CHUY): Are These Top Post-IPO Performers Still a Buy?

Investors are no stranger to large IPO pops, but in the last year we have seen incredible post-IPO runs, indicating that these companies were priced too cheap. Thus I am looking at the top five to determine if more upside exists.

#5 Ambarella Inc (NASDAQ:AMBA)

Since its IPO on Oct. 10, 2012, the technology company Ambarella Inc (NASDAQ:AMBA) has rallied 154.6%. Currently the stock is trending higher and is just $0.74 from reaching new highs of $16.00. With that said, this is a company that is trading at just 3.40 times sales and 25 times earnings.

The company has sales growth of more than 25% and continues to see margin improvements. Thus I say that it is very possible that this large post-IPO performer continues to tick higher.

#4 Chuy’s Holdings Inc (NASDAQ:CHUY)

Chuy’s Holdings Inc (NASDAQ:CHUY) is a restaurant serving what it calls “Tex Mex” food, and its growth has been remarkable. As a result of its 25% top-line growth, the stock has responded with a 156.54% post-IPO gain. Despite these gains the stock trades at just 3 times sales and 60 times earnings (with margins rapidly improving).

My only problem with the company is that its comparable store sales are only growing 2.30%, meaning most of its growth comes from expansion. With that said, the stock is still cheap for a company with 25% top line growth, hence I’d still be a buyer.


TESARO Inc (NASDAQ:TSRO) is a zero-revenue-producing clinical stage biotechnology company that has gained 166% since its IPO. The company’s lead product is Rolapitant, a Phase 3 drug for nausea and vomiting associated with chemotherapy. Then, it has an early stage drug that treats breast and ovarian cancers, which is far from an FDA approval.

The problem is that this developmental company trades with a valuation over $1 billion and seeks stiff competition from Merck if its drug Rolapitant makes it to market. Therefore, with limited sales potential short-term, I’d say sell this rally.

#2 Shutterstock Inc (NYSE:SSTK)

Shutterstock Inc (NYSE:SSTK) is a marketplace for commercial digital imagery, and has seen its valuation increase 190.12% since its IPO. The company is growing at about 35% year-over-year, and has both strong margins and consistent improvements in margins. The stock trades at 47 times next year’s earnings and 9 times sales, hence I do think it is a bit expensive compared to growth.

Both Ambarella Inc (NASDAQ:AMBA) and Chuy’s Holdings Inc (NASDAQ:CHUY) have high 20% growth and trade at just 3 times sales, therefore I don’t think Shutterstock Inc (NYSE:SSTK) is worth the premium.

#1 SolarCity Corp (NASDAQ:SCTY)

No other post-IPO performer even comes close to the gains of SolarCity Corp (NASDAQ:SCTY), a stock that has rallied an incredible 462.50%. The company is engaged in the design, installation and sale or lease of solar energy systems to residential and commercial customers.

While this could eventually become a highly lucrative business, it is currently producing growth of less than 25%. Furthermore, the company is nowhere near profitable, having operating margins of negative (53.52%). Thus I can’t find any reason to buy after this rally, especially considering its price/sales ratio of 21.0. The stock is simply too expensive.


I explain in my book, Taking Charge With Value Investing(McGraw-Hill, 2013), that contrary to popular belief, IPOs can offer some of the best opportunities in the market. Of course this is dependent upon the industry, but companies that decide to become public are usually at exciting times in their history and then have large amounts of cash to invest in the company from the IPO. With that said, you must continue to monitor such companies, and be ready to take profits if a stock becomes too expensive (hence SolarCity Corp (NASDAQ:SCTY)). Overall, it’s a market that investors should explore with immense interest.

The article Are These Top Post-IPO Performers Still a Buy? originally appeared on and is written by Brian Nichols.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.